文献速递消化系统肿瘤

CRISPR/Cas9构建ARID1A缺陷人胃类器官模型揭示致癌转化机制

A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation.
PubMed 文献 · Cancer Discov · 2021-01-15

该研究在TP53-/-人胃原代类器官中用CRISPR/Cas9敲除ARID1A,诱导形态学异型增生、致瘤性和黏液性分化。WNT/β-catenin激活仅挽救黏液性分化而不挽救过度增殖,提示存在旁路途径。高通量化合物筛选显示ARID1A缺陷类器官对BIRC5/survivin抑制选择性敏感,提示FOXM1/BIRC5驱动的增殖是ARID1A敲除早期致瘤的关键介质。

要点

  • ARID1A敲除联合TP53缺失即可诱导人胃类器官异型增生与致瘤性。
  • WNT激活仅逆转黏液分化,不逆转增殖,提示转化存在独立通路。
  • ARID1A缺陷类器官对BIRC5/survivin抑制选择性敏感。

核心结论

  • ARID1A敲除下游存在两条通路:WNT抑制的黏液性分化为非必需,FOXM1/BIRC5驱动的增殖为必需。

研究设计与样本

  • 在TP53-/-人胃原代类器官中行CRISPR/Cas9介导ARID1A敲除,并结合系统生物学与小分子筛选。

主要发现

  • ARID1A敲除诱导形态学异型增生、致瘤性和黏液性分化。
  • WNT/β-catenin激活挽救黏液性分化但不挽救过度增殖。
  • ARID1A突变诱导微卫星不稳定及EBV相关亚型特征性转录模块,包括FOXM1相关有丝分裂基因和BIRC5/survivin。
  • 高通量化合物筛选显示ARID1A缺陷类器官对BIRC5/survivin抑制选择性敏感。

临床怎么用

  • 提示ARID1A缺陷早期胃癌中BIRC5/survivin通路可作为潜在干预靶点,尚需临床验证。

局限性

  • 研究基于体外类器官模型,非临床人体数据,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in ARID1A rank among the most common molecular aberrations in human cancer. However, oncogenic consequences of ARID1A mutation in human cells remain poorly defined due to lack of forward genetic models. Here, CRISPR/Cas9-mediated ARID1A knockout (KO) in primary TP53-/- human gastric organoids induced morphologic dysplasia, tumorigenicity, and mucinous differentiation. Genetic WNT/β-catenin activation rescued mucinous differentiation, but not hyperproliferation, suggesting alternative pathways of ARID1A KO-mediated transformation. ARID1A mutation induced transcriptional regulatory modules characteristic of microsatellite instability and Epstein-Barr virus-associated subtype human gastric cancer, including FOXM1-associated mitotic genes and BIRC5/survivin. Convergently, high-throughput compound screening indicated selective vulnerability of ARID1A-deficient organoids to inhibition of BIRC5/survivin, functionally implicating this pathway as an essential mediator of ARID1A KO-dependent early-stage gastric tumorigenesis. Overall, we define distinct pathways downstream of oncogenic ARID1A mutation, with nonessential WNT-inhibited mucinous differentiation in parallel with essential transcriptional FOXM1/BIRC5-stimulated proliferation, illustrating the general utility of organoid-based forward genetic cancer analysis in human cells. SIGNIFICANCE: We establish the first human forward genetic modeling of a commonly mutated tumor suppressor gene, ARID1A. Our study integrates diverse modalities including CRISPR/Cas9 genome editing, organoid culture, systems biology, and small-molecule screening to derive novel insights into early transformation mechanisms of ARID1A-deficient gastric cancers.See related commentary by Zafra and Dow, p. 1327.This article is highlighted in the In This Issue feature, p. 1307.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Lo YH, Kolahi KS, Du Y, et al. A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation. Cancer Discov. 2021. PMID: 33451982. doi:10.1158/2159-8290.CD-20-1109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。